{"product_id":"muscle-aging-inclusionbody-myositis-and-myopathies-9781405196468","title":"Muscle Aging InclusionBody Myositis and","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eMuscle weakness with ageing is almost inevitable, generally beginning to manifest beyond the age of 40, and is usually unstoppable. It can lead to reduced mobility, increased risk of falling, injury, and even death. But you're just getting old is not a sufficient diagnosis. Specific causes of neuromuscular symptoms may explain progressive muscle weakness, and should be investigated for potential treatment.\u003cbr\u003e \u003cbr\u003e   \u003cp\u003e\u003cb\u003e\u003ci\u003eMuscle Ageing, Inclusion-Body Myositis and Myopathies\u003c\/i\u003e\u003c\/b\u003e explores the clinical and pathological expression of muscle weakness in aging persons. Case studies demonstrate how physicians can more accurately diagnose weakening elderly patients and make better management decisions.\u003c\/p\u003e \u003cp\u003eIt also explores sporadic inclusion-body myositis and hereditary inclusion-body myopathies. The former, the most common progressive muscle disease in the over 50s, is frequently under-diagnosed and, with the increasing population of aged individuals, is presenting a greater c\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003eList of Contributors, vii  \u003c\/p\u003e\u003cp\u003ePreface, xi\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 1 Muscle Aging\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1 Aging of the human neuromuscular system: pathological aspects, 3\u003cbr\u003e \u003ci\u003eW. King Engel and Valerie Askanas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 Aging of the human neuromuscular system: clinical considerations, 33\u003cbr\u003e \u003ci\u003eW. King Engel and Valerie Askanas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 Aging of the human neuromuscular system: patient vignettes, 55\u003cbr\u003e \u003ci\u003eW. King Engel, Shalini Mahajan, and Valerie Askanas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 Mitochondrial changes in aging with particular reference to muscle, and possible clinical consequences, 81\u003cbr\u003e \u003ci\u003eSalvatore DiMauro, Eric Schon, and Michio Hirano\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 Protein degradation in aging cells and mitochondria: relevance to the neuromuscular system, 89\u003cbr\u003e \u003ci\u003eJenny K. Ngo and Kelvin J. A. Davies\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 Human muscle protein metabolism in relation to exercise and aging: potential therapeutic applications, 97\u003cbr\u003e \u003ci\u003eMicah J. Drummond and Blake B. Rasmussen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 2 Sporadic Inclusion-Body Myositis\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7 Pathogenesis of sporadic inclusion-body myositis: role of aging and muscle-fiber degeneration, and accumulation of the same proteins as in Alzheimer and Parkinson brains, 111\u003cbr\u003e \u003ci\u003eValerie Askanas, W. King Engel, and Anna Nogalska\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 Inflammatory and autoimmune features of inclusion-body myositis, 146\u003cbr\u003e \u003ci\u003eMarinos C. Dalakas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 Sporadic inclusion-body myositis: clinical symptoms, physical findings, and diagnostic investigations, 159\u003cbr\u003e \u003ci\u003eFrank L. Mastaglia\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 Pathologic diagnostic criteria of sporadic inclusion-body myositis and hereditary inclusion-body myopathy muscle biopsies, 168\u003cbr\u003e \u003ci\u003eValerie Askanas and W. King Engel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePart 3 Hereditary Inclusion-Body Myopathies\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e11 Function and mutations of the GNE gene leading to distal myopathy with rimmed vacuoles\/hereditary inclusion-body myopathy, animal models, and potential treatment, 177\u003cbr\u003e \u003ci\u003eMay Christine V. Malicdan, Satoru Noguchi, and Ichizo Nishino\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 GNE myopathy (hereditary inclusion-body myopathy\/distal myopathy with rimmed vacuoles): clinical features and epidemiology, 191\u003cbr\u003e \u003ci\u003eZohar Argov, Ichizo Nishino, and Ikuya Nonaka\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 Consequences of the hereditary inclusion-body myopathy-characteristic GNE mutations on muscle proteins in vivo and in vitro, 199\u003cbr\u003e \u003ci\u003eAldobrando Broccolini and Massimiliano Mirabella\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 Function and structure of VCP mutations leading to inclusion-body myopathy associated with Paget disease of bone and frontotemporal dementia, 206\u003cbr\u003e \u003ci\u003eCezary Wojcik\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 Clinical spectrum of VCP myopathy, Paget disease, and frontotemporal dementia: experimental models and potential treatments, 219\u003cbr\u003e \u003ci\u003eVirginia E. Kimonis, Eric Dec, Mallikarjun Badadani, Angele Nalbandian, Jouni Vesa, Vincent Caiozzo, Douglas Wallace, Barbara Martin, Charles Smith, and Giles D. Watts\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Drosophila and mouse models of hereditary myopathy caused by mutations in VCP\/p97, 230\u003cbr\u003e \u003ci\u003eNisha M. Badders and J. Paul Taylor\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex, 241\u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407929811287,"sku":"9781405196468","price":100.76,"currency_code":"GBP","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781405196468.jpg?v=1730500991","url":"https:\/\/bookcurl.com\/products\/muscle-aging-inclusionbody-myositis-and-myopathies-9781405196468","provider":"Book Curl","version":"1.0","type":"link"}